Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sabirnetug - Acumen Pharmaceuticals

X
Drug Profile

Sabirnetug - Acumen Pharmaceuticals

Alternative Names: ACU-193; Alzheimer's disease immunotherapy - Acumen Pharmaceuticals; anti-ADDL antibodies; HuC-091

Latest Information Update: 11 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Northwestern University
  • Developer Acumen Pharmaceuticals
  • Class Antidementias; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease

Most Recent Events

  • 12 Apr 2024 Updated efficacy data from the phase I INTERCEPT-AD trial in Alzheimer's disease presented at the 76th Annual Meeting of the American Academy of Neurology (AAN-2024)
  • 26 Mar 2024 Acumen Pharmaceuticals plans a phase II ALTITUDE-AD trial for Alzheimer's disease in USA (Intravenous, Infusion) in 1H 2024
  • 26 Mar 2024 Acumen Pharmaceuticals plans a phase I trial for Alzheimer's disease (SC) in mid-2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top